Cost-Effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration in Japan

Cost-Effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration in Japan

Abstract Introduction Neovascular age-related macular degeneration (nAMD) is the world’s leading cause of blindness in elderly people. While anti-vascular endothelial growth factor (VEGF) treatments are used as the first option for patients with nAMD, they are generally expensive and need repeated i...

Full description

Bibliographic Details
Main Authors: Yasuo Yanagi, Kanji Takahashi, Tomohiro Iida, Fumi Gomi, Junko Morii, Eriko Kunikane, Taiji Sakamoto
Format: Article
Language:English
Published: Adis, Springer Healthcare 2023-05-01
Series:Ophthalmology and Therapy
Subjects:
Cost-effectiveness
Costs and cost analysis
Dosing regimens
Japan
Markov model
Neovascular age-related macular degeneration
Online Access:https://doi.org/10.1007/s40123-023-00715-y

Internet

https://doi.org/10.1007/s40123-023-00715-y

Similar Items